DZD, an infectious disease diagnostics company harnessing the power of whole-genome sequencing and AI to combat the rise of antibiotic-resistant infections, announced today the recent completion of a $16M round of financing. This latest financing brings the total raised by Day Zero Diagnostics to $49M in venture capital funding and over $18M in non-dilutive funding.
Overview A US biotech company's Phase I oncology study had stalled under the management of…
Overview A US biotech company's Phase I oncology study had stalled under the management of…
The APAC region continues to play a critical role in the global landscape of drug…
The APAC region continues to play a critical role in the global landscape of drug…